CSIMarket Company Name, Ticker, Industry, else..
 
Aditxt Inc   (NASDAQ: ADTX)
 
Price: $0.0066 $0.00 -5.714%
Day's High: $0.007300000172108412 Week Perf: -17.5 %
Day's Low: $ 0.01 30 Day Perf: 120 %
Volume (M): 1,463,447 52 Wk High: $ 27,092.88
Volume (M$): $ 0 52 Wk Avg: $2,773.58
Open: $0.01 52 Wk Low: $0.00



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 0
 Employees 26
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -53
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Aditxt Inc is a biotechnology company based in the United States. The company specializes in developing innovative technologies and solutions in the field of health diagnostics. Aditxt focuses on leveraging its Immune Monitoring BioSensor Platform to develop advanced diagnostics tests that can provide information about an individual's immune system health. Their aim is to improve disease detection and monitoring, medication efficacy, and personalized medicine. The company's technology combines bioinformatics, immunology, and data science to provide insights into an individual's immune system functioning and overall health. Aditxt Inc aims to revolutionize the healthcare industry through its cutting-edge diagnostics solutions.


   Company Address: 737 N. Fifth Street Richmond 23219 VA
   Company Phone Number: 870-1200   Stock Exchange / Ticker: NASDAQ ADTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        0.61% 
ACRV        1.21% 
AKTX        2.9% 
ALT        5.63% 
ETON   -3.4%    
ZVRA        7.83% 
• View Complete Report
   



Business Update

Advancing Ovarian Cancer Diagnostics Aditxts Pearsanta Receives DoD Pilot Award Proposal Invitation

Published Thu, Jul 24 2025 3:43 PM UTC

: Aditxt, Inc. (NASDAQ: ADTX), a company known for its commitment to accelerating health innovations, has announced a milestone achievement by its subsidiary, Pearsanta, Inc. Pearsanta has received an invitation to submit a full proposal for the Congressionally Directed Medical Research Programs (CDMRP) Ovarian Cancer Research Program (OCRP) Pilot Award, funded by the U.S. D...
Business Update

Progress Amid Challenges Aditxt and Adimunes Journey Towards Innovation in Health Care

Published Mon, May 5 2025 6:42 AM UTC

In a landscape where biopharmaceutical companies are under constant scrutiny for their growth and innovation, Aditxt Inc. (NASDAQ: ADTX) is making strides in advancing its therapeutic candidate, ADI-100, despite facing financial headwinds. As part of its ongoing commitment to transparency and collaboration, Aditxt recently announced a Weekly Update event featuring Dr. Shahro...
Business Update

Aditxts Recent Developments Compliance Regained but Revenue Challenges Persist in Q2 2024

Published Sat, Apr 12 2025 3:16 AM UTC

Aditxt Weekly Update: Navigating Compliance and Market Dynamics In a recent update released from Mountain View, California, Aditxt, Inc. (NASDAQ: ADTX) shared pivotal developments in its ongoing journey as a social innovation platform committed to accelerating promising health innovations. A critical focus of the update was the company’s regained compliance with Nasdaq s m...
Business Update

Aditxt Regains Nasdaq Compliance and Improves Financial Performance with Significant Revenue Gains,

Published Fri, Apr 11 2025 6:26 PM UTC

Aditxt Regains Compliance with Nasdaq as Financial Performance Shows Improvement MOUNTAIN VIEW, Calif. Aditxt, Inc. (NASDAQ: ADTX), a company dedicated to accelerating promising health innovations through a social innovation platform, recently announced significant updates that are poised to impact its standing in the market. In its latest Aditxt Weekly Update, the company...
Business Update

Aditxt Focuses on Pearsantas Acquisition of the CaSe Platform and Announces Plans for Public Offering in 2...

Published Sat, Mar 29 2025 4:46 AM UTC

Aditxt Highlights Pearsanta s Acquisition of the CaSe Platform and Future IPO Plans Aimed at Transforming Early Cancer Detection In a significant development for cancer diagnostics and therapeutics, Aditxt, Inc. (NASDAQ: ADTX) has announced that today s Aditxt Weekly Update will spotlight the acquisition of the CaSe Platform by its subsidiary, Pearsanta, Inc. The technology,...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 0.00
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 0.01
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.02
Working Capital Ratio 0.07
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 180487.04 $
Revenues (TTM) 0.71 $
Cash Flow (TTM) -
Cash 13.31 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 554
Net Income per Employee (TTM) -2,039,373
Receivable Turnover Ratio (TTM) 0.23
Inventory Turnover Ratio (TTM) 0.31
Asset Turnover Ratio (TTM) 0

Profitability Ratios Current
Gross Margin (MRQ) 23.77 %
Operating Margin (MRQ) -35753.28 %
Net Margin (MRQ) -132698.36 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.